We aimed to understand how N-acetyl glucosamine (GlcNAc), a compound known for its anti-inflammatory properties, affects the development and severity of collagen-induced arthritis (CIA). Our investigation involved applying a special multivalent GlcNAc-terminated glycoconjugate and assessing its influence through various methodologies.
The results were promising. We observed that GlcNAc treatment significantly reduced inflammation at the site of arthritis, notably decreasing the presence of immune cells that contribute to the disease. Furthermore, it appeared to hinder the activation of other immune cells, which are often involved in the production of harmful pro-inflammatory molecules.
Additionally, GlcNAc treatment not only delayed the onset of arthritis symptoms but also eased the severity of these symptoms in many cases. We found that about 18% to 31% of participants treated with GlcNAc completely avoided any arthritis symptoms. Overall, our findings support a new approach to managing arthritis by focusing on the glycobiological aspects of treatment, presenting GlcNAc as a potential therapeutic option for those suffering from this debilitating condition.
Slowed progression
Most Useful Review
Works for my osteoarthritis. I've used this for several years for the osteoarthritis in my hands, and it seems to have significantly slowed the progression of the bumps on my knuckles. I use it alongside SAM-e.